Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist

about

Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist

Item

http://www.wikidata.org/entity/Q58692179

description

im November 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 29 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Pharmacological characterizati ...... hrombopoietin receptor agonist

@en

Pharmacological characterizati ...... hrombopoietin receptor agonist

@nl

type

Item

label

Pharmacological characterizati ...... hrombopoietin receptor agonist

@en

Pharmacological characterizati ...... hrombopoietin receptor agonist

@nl

prefLabel

Pharmacological characterizati ...... hrombopoietin receptor agonist

@en

Pharmacological characterizati ...... hrombopoietin receptor agonist

@nl

P1476

Pharmacological characterizati ...... hrombopoietin receptor agonist

@en

P2093

Chengying Xie

http://www.w3.org/2001/XMLSchema#string

Haoyu Fu

http://www.w3.org/2001/XMLSchema#string

Huajun Zhao

http://www.w3.org/2001/XMLSchema#string

Xubin Bao

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily

Thrombopoietin signal transduction requires functional JAK2, not TYK2

Thrombocytopenia caused by the development of antibodies to thrombopoietin.

Diagnosis and management of aplastic anemia and myelodysplastic syndrome.

Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.

The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.

Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy.

Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights.

Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.

Programmed anuclear cell death delimits platelet life span.

P304

5367-5377

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JCMM.13809

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Liguang Lou

P577

2018-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30156363

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

molecular medicine

P932

6201220

http://www.w3.org/2001/XMLSchema#string